Capecitabine

Drug #1493

Capecitabine is an antimetaboite antineoplastic (anticancer) drug,which is metabolised to fluorouracil. Capecitabine is given by mouth and used as amonotherapy for metastatic colorectal carcinoma. Capecitabine is also licensed for second line treatment of locally advanced or metastatic breast cancer either in combination ao alone.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 359.4 · Non-proprietary name: Capecitabine.

Pharmacokinetics

None recorded.

Indications

Capecitabine is primarily indicated in conditions like Breast cancer, Metastatic, Metastatic colorectal cancer.

Contraindications

None recorded.

Dosage

Capecitabine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.25 g/m2	1.25 g/m2	Every 12h	PO	For 14 days. Subsequent courses repeated after 7-day interval.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown1 interaction

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Capecitabine in overdosage may give rise to further complications which include Hyperbilirubinemia, Thrombocytopenia .

Capecitabine is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Anorexia , Constipation , Dermatitis, Desquamation of hands, Diarrhea, Erythema, Eye irritation, Fatigue, Fever, Nausea, Paresthesias, StomatitisX, Vomiting .

Warnings / Precautions

Avoid use in patient with a history of hypersensitivity to capecitabine, fluorouracil or any component. It is classified as pregnancy category D and should be used only when the benefit of therapy outweigh the risk to fetus.

Available Brands

None recorded.

Storage Conditions

Capecitabine should be stored .

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs